Sponsor or institution

Clinical trials and research at Ascendis Pharma A/S

• 8Clinical trials
• 19Countries

Newest trials

All recruiting trials (8)

• Palopegteriparatide in adolescents with long-term hypoparathyroidism

  This study tests whether a once-daily palopegteriparatide shot helps adolescents with long‑standing hypoparathyroidism and whether it’s safe for them.

  Recruiting at 3 sites Phase 3 Ascendis Pharma A/S · Bron and 2 other locations · NCT07706764

• Pregnancy registry tracking outcomes after YORVIPATH exposure during pregnancy and breastfeeding

  This registry collects information from pregnant or breastfeeding people with hypoparathyroidism who took YORVIPATH to see if the exposure affects pregnancy, the baby, or infant outcomes through the first year of life.

  Recruiting Ascendis Pharma A/S · Morgantown, West Virginia · NCT07345494

• Palopegteriparatide levels in breast milk of lactating individuals taking YORVIPATH.

  This will see if palopegteriparatide (YORVIPATH) appears in the breast milk of lactating adults with hypoparathyroidism who are breastfeeding.

  Recruiting Ascendis Pharma A/S · Morgantown, West Virginia · NCT07264634

• Once-weekly lonapegsomatropin versus daily somatropin for children and adolescents with short stature due to growth-hormone-sufficient conditions

  It will test whether a once-weekly injection of lonapegsomatropin helps children and teens with Turner syndrome, SHOX mutation, small-for-gestational-age, or idiopathic short stature grow as well as or better than daily somatropin.

  Recruiting at 56 sites Phase 3 Ascendis Pharma A/S · Phoenix, Arizona and 55 other locations · NCT07221851

• Higher-dose palopegteriparatide treatment for adults with hypoparathyroidism.

  This 78-week test will see if giving adults with chronic hypoparathyroidism higher doses of palopegteriparatide (above 30 µg/day) is safe and better controls their calcium levels.

  Recruiting at 10 sites Phase 3 Ascendis Pharma A/S · Greeley, Colorado and 9 other locations · NCT07081997

• Evaluating a new treatment for infants with achondroplasia

  This study is testing a new treatment for infants with achondroplasia to see if it helps them grow better compared to a placebo.

  Recruiting at 18 sites Phase 2 Ascendis Pharma A/S · Saint Paul, Minnesota and 17 other locations · NCT06079398

• Observational study on the effectiveness and safety of SKYTROFA for growth hormone deficiency

  This study is testing how well and safely SKYTROFA works for people with growth hormone deficiency by looking at their experiences during regular treatment.

  Recruiting at 27 sites Ascendis Pharma A/S · Phoenix, Arizona and 26 other locations · NCT05820672

• Long-term safety assessment of lonapegsomatropin in children with growth hormone deficiency

  This study looks at the long-term safety of lonapegsomatropin in children with growth hormone deficiency who are already being treated with it.

  Recruiting at 27 sites Ascendis Pharma A/S · Phoenix, Arizona and 26 other locations · NCT05775523

Quick answers

How many clinical trials run by Ascendis Pharma A/S are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 19 countries. The most sites are in United States (7 trials), France (3 trials), Germany (2 trials), Italy (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →